Therapies for Long COVID in non-hospitalised individuals: from symptoms, patient-reported outcomes and immunology to targeted therapies (The TLC Study)

INTRODUCTION: Individuals with COVID-19 frequently experience symptoms and impaired quality of life beyond 4–12 weeks, commonly referred to as Long COVID. Whether Long COVID is one or several distinct syndromes is unknown. Establishing the evidence base for appropriate therapies is needed. We aim to...

Descripción completa

Detalles Bibliográficos
Autores principales: Haroon, Shamil, Nirantharakumar, Krishnarajah, Hughes, Sarah E, Subramanian, Anuradhaa, Aiyegbusi, Olalekan Lee, Davies, Elin Haf, Myles, Puja, Williams, Tim, Turner, Grace, Chandan, Joht Singh, McMullan, Christel, Lord, Janet, Wraith, David C, McGee, Kirsty, Denniston, Alastair K, Taverner, Thomas, Jackson, Louise J, Sapey, Elizabeth, Gkoutos, George, Gokhale, Krishna, Leggett, Edward, Iles, Clare, Frost, Christopher, McNamara, Gary, Bamford, Amy, Marshall, Tom, Zemedikun, Dawit T, Price, Gary, Marwaha, Steven, Simms-Williams, Nikita, Brown, Kirsty, Walker, Anita, Jones, Karen, Matthews, Karen, Camaradou, Jennifer, Saint-Cricq, Michael, Kumar, Sumita, Alder, Yvonne, Stanton, David E, Agyen, Lisa, Baber, Megan, Blaize, Hannah, Calvert, Melanie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Infectious Diseases
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9044550/
https://www.ncbi.nlm.nih.gov/pubmed/35473737
http://dx.doi.org/10.1136/bmjopen-2021-060413

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9044550/
https://www.ncbi.nlm.nih.gov/pubmed/35473737
http://dx.doi.org/10.1136/bmjopen-2021-060413

Ejemplares similares